Yeast metabolic products, yeast antigens and yeasts as possible triggers for irritable bowel syndrome
Eur J Gastroenterol Hepatol 2005; 17(1): 21-26
Santelmann, Heiko and Mclaren Howard, John
Many patients with irritable bowel syndrome (IBS) are disillusioned by the lack of efficacy of treatments and suffer from numerous symptoms not covered by the Rome criteria for IBS, as the current empirical treatment regimes fail to address these persistent deliberating ‘IBS associated symptoms’. These symptoms are similar to other symptom complexes like chronic fatigue and the so called ‘candida syndrome’, and many seek help from alternative medicine. The possible role of Candida and yeasts in non-immune compromised individuals is disputed and is the subject of this review.
Even if the involvement of yeasts in the aetiology of IBS still remains unclear, there is increasing evidence for yeasts being able to cause IBS-symptoms in sensitised patients via Candida products, antigens and cross-antigens. But more research is needed before antifungal treatment can be recommended as a first line treatment for IBS.
NOTICE : Biolab Limited has gone into administration
14th July 2022
Biolab Limited has gone into administration due to the delay by The Care Quality Commission in processing our application to transfer our business activities to our laboratory site in West London following an earlier temporary suspension.
We always remained highly confident that Biolab would reopen and invested heavily in relocating the business, retaining and retraining our employees, developing new and improved methods of work and updating our documentation, so this comes as a huge disappointment for us all, but as you’ll appreciate no business can continue indefinitely without an income.
We are no longer able to process any samples for testing.
Biolab is very proud of the help we have given to hundreds of thousands of patients over 37 years, and we thank everyone for their phenomenal support and loyalty over the years, and for the hundreds of messages of support we have received in recent months.